Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $59.83.

CTLT has been the topic of a number of analyst reports. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Finally, StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research report on Wednesday.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent in the second quarter valued at approximately $42,000. Sentry Investment Management LLC acquired a new position in Catalent in the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC raised its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in shares of Catalent in the third quarter valued at about $73,000.

Catalent Stock Up 2.5 %

CTLT stock opened at $59.95 on Thursday. Catalent has a fifty-two week low of $32.38 and a fifty-two week high of $61.20. The company’s 50 day moving average price is $60.03 and its 200 day moving average price is $58.03. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The firm has a market capitalization of $10.88 billion, a price-to-earnings ratio of -10.92, a PEG ratio of 2.06 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) earnings per share. On average, equities research analysts anticipate that Catalent will post 0.95 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.